Select Field
Select Ministry
12 results
Our technology focuses on assessment of wound healing status in chronic wound care. It employs multispectral imaging principles to provide healthcare professionals with blood oxygen saturation information. By training AI algorithms on clinical patient data collected at NCKU Hospital, we conduct wound tissue recognition and healing assessment. Through miniaturized systems and IoT technology, the technology enables continuous wound tracking and achieving the goal of remote healthcare.
Future Tech | Information ＆ CommunicationsThis invention introduces a method for producing activated carbon using microwave technology and carbonated water. Compared to traditional high-temperature and strong acid or base activation processes, this method is more environmentally friendly and safer. The pore structure of the carbonized material expands rapidly under microwaves, and the mild acidic environment from the carbonated water enhances adsorption capacity. This approach reduces activation time and energy consumption, with broad applications in water and air purification.
Future Tech | Biotechnology ＆ Medical careThe "Blood Circulation Imaging System" combines optical and laser systems with advanced imaging to effectively monitor blood circulation in elderly individuals. Its non-invasive measurement quickly identifies microcirculation issues, offering important guidance for wound care and early detection of peripheral vascular disease risks. Through telemedicine, it expands assessment tools to improve health management in elderly communities, ultimately enhancing their quality of life.
Future Tech | Biotechnology ＆ Medical careThis system revolutionizes sports teaching with AI-enabled equipment, including smart racquets, AI cameras, AI shuttlecock machines, and a cloud platform. By combining deep learning and 3D posture estimation, it creates learner-centric programs and automated evaluations. It records and assesses training progress, enhancing skills and knowledge while quantifying performance metrics to boost athletic performance.
Future Tech | Life ApplicationThis technology involves an oral available developmental drug candidate, DBPR728, that demonstrated in vivo efficacy in promoting the degradation of the MYC oncoprotein and inhibiting glycolysis of cancer cells, thereby inducing cancer cell apoptosis. Clinically, this technology primarily targets diseases such as small cell lung cancer and triple-negative breast cancer, which acquired MYC gene amplification.
Future Tech | Biotechnology ＆ Medical careThe combination of CpG-2722 and 2’3’-c-di-AM(PS)2 exhibited a cooperative adjuvant effect for SARS-CoV-2 RBD vaccines and a favorable safety profile in the nasal cavities of mice. CpG-2722/cyclic dinucleotide combinations enhanced the performance of nasal H7 influenza vaccines. Nasal administration of these combination-adjuvanted shingles vaccines elicited a superior vaccine response compared to intramuscularly injected Shingrix, indicating the superior adjuvant activity of these combinations.
Future Tech | Biotechnology ＆ Medical careDBPR807, a highly selective, safe, and potent CXCR4 antagonist, possesses in vivo efficacy under various HCC settings with supreme benefits on combination therapy, whereby it can significantly synergize with not only antiangiogenic therapy (sorafenib) but also immunotherapy (anti–PD-1) to further extend overall survival. DBPR807 can significantly suppress tumor growth, prevent metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. Our results suggest the clinical potential of DBPR807 for the treatment of HCC.
Future Tech | Biotechnology ＆ Medical careThe invention describes a potent, orally bioavailable small molecule isoQC inhibitor targeting the CD47-SIRP⍺ immune checkpoint signal. DBPR22998 effectively inhibits isoQC enzyme activity, thereby reducing the binding of CD47 and SIRPα on the surface of tumor cells and the "don＇t eat me" signal. DBPR22998 is best used in combination with monoclonal antibody-targeted drugs or immune checkpoint antibodies to promote antibody-dependent cell phagocytosis and enhance tumor elimination.
Future Tech | Biotechnology ＆ Medical careTo examine the expression levels of LDOC1 in EGFR mutated NSCLC tumors using IHC with customized anti-LDOC1 antibodies or using quantitative PCR methods.
Future Tech | Biotechnology ＆ Medical careThe present invention relates to a method for decreasing the abuse liability and psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methyl glycine derivative. The combination can be applied in the treatment of treatment-resistant depression/bipolar disorders, anxiety disorders and pain.
Future Tech | Biotechnology ＆ Medical careWe introduce a hanging-drop-based microfluidic co-culture (μ-CCD) chip technology generating uniform 3D cell spheroids in top-layer hanging droplets, merging and co-culturing them in the bottom-layer hanging droplets. The liquid added to the confrontation channels contacts the droplets, overcomes the surface tension, and merges spheroids into the newly formed hanging droplets of the bottom layer, minimizing manual intervention that may affect the reproducibility and viability of cell spheroids.
Future Tech | Biotechnology ＆ Medical careThis project has successfully established National biobank consortium of Taiwan (NBCT) through the fund support and governance from the government. Currently NBCT already includes 37 biobanks and has more than 989 thousand participants. So far, NBCT already received 184 applications, including 32 from industries.One of them is an international collaboration project and application from Roche. The number of specimens in the NBCT is very large, coupled with large medical data, it is already Taiwan's largest biomedical industry resource.
Future Tech | Biotechnology ＆ Medical careComing soon!
